Dataset opportunity
Robsurgical — 医疗影像数据集机会
Robsurgical 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球医疗影像人工智能市场 = 2024 年为 17.0 亿美元，复合年增长率为 25.8%（来源：Global Market Direct）
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-22
Time runs out for Vicarious Surgical
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能和诊断影像公司
Robsurgical 持有用于手术应用的专有医疗影像数据集，该数据集整合了丰富的图像集以及来自手术设备和相关`医疗记录`的上下文物联网数据。这种多模态组合为开发和验证高精度诊断人工智能模型提供了全面的基础，提供了对高级自动化诊断至关重要的深入临床见解。
全球医疗影像人工智能市场是一个快速扩张的领域，2024 年市场价值为17.0 亿美元，预计将以25.8% 的复合年增长率增长。[3] 尽管由于数据集的商业前状态（CE 标志待定）以及需要严格遵守GDPR和先进的匿名化协议而存在访问复杂性，但其临床深度和稀有性对于旨在从这个高增长市场中获利的 AI 开发人员来说，代表着显著的竞争优势。[3] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：商业前状态（CE 标志待定）限制了当前的数据商业流动；医疗数据受严格的医疗保健法规和 GDPR 管辖；手术视频需要先进的匿名化 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Robsurgical 持有其 Bitrack 手术机器人临床试验的专有医疗影像数据集。这些独特的数据，特别是来自泌尿外科手术（如肾切除术）的数据，是医疗人工智能公司开发下一代诊断人工智能和手术分析工具的关键资产。在一个预计到 2024 年将达到 17.0 亿美元且年增长率超过 25% 的市场中，这种稀有、特定手术的视觉数据为下一代诊断工具的培训提供了显著的竞争优势。
See dimension details ↓- Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求异常高，这得益于医疗影像人工智能市场的快速扩张（复合年增长率为 25.8%），从而产生了对独特、高质量临床数据以培训下一代诊断工具的强烈需求。[3]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=已拥有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据胃口信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - ICP Audit100
✓ 良好目标 — 这是一个理想的目标：一家 MedTech 中小型企业，其核心业务是销售手术机器人，该机器人作为副产品产生了大量有价值的、休眠的运营和影像数据。问题：公司网站提到专注于数字化，包括“人工智能、大数据、医疗影像、视觉系统和虚拟现实”[15]。
- Deep Qualification80
⚠ 需要审查 — Rob Surgical 是一家商业前医疗设备制造商，而非数据销售商。它开发了 Bitrack 手术机器人，在试验期间产生的相关影像和运营数据是休眠的副产品。最近的 CE 标志批准是商业化的主要触发因素，但根据 GDPR 和医疗法规，数据访问仍然受到高度限制，并且从公开来源来看，所有权尚不明确。[业务模式 = 工具供应商]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
这些证据指向手术机器人的时间序列运营数据，这对于培训人工智能分析和改进机器人手术效率非常有价值。
Image collection
这证实了来自涉及肾切除术的临床试验的专有图像的存在，这是任何构建手术诊断人工智能的公司的一项核心资产。
Medical records / imaging
这些证据将数据集与高价值的泌尿外科专业联系起来，提供了培训和验证专业手术人工智能模型所需的具体手术背景。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Robsurgical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.70 Billion in 2024, CAGR 25.8% (source: Global Market Direct). Investment score 68.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Er3I — 维护日志数据集机会
View opportunity →工业Anesco — 维护日志数据集机会
View opportunity →出行Groupelml — 交易数据集机会
View opportunity →